- Home
- AEMD vs NXTS Comparison
AEMD vs NXTS Comparison
Compare AEMD & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | NXTS |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 9 |
| Industry | Medical/Dental Instruments | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.3M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | AEMD | NXTS |
|---|---|---|
| Price | $2.24 | $4.63 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 23.9K | 19.7K |
| Earning Date | 02-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.55 |
| 52 Week High | $5.89 | $6.21 |
Technical Indicators
Market Signals| Indicator | AEMD | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 61.39 |
| Support Level | $2.18 | $3.92 |
| Resistance Level | $2.46 | $5.31 |
| Average True Range (ATR) | 0.11 | 0.62 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 25.00 | 42.82 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.